We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson
News

AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson

AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson
News

AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AdipoGenix Inc. has announced the achievement of its third milestone in the Company's drug discovery collaboration with Johnson & Johnson.

In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell- based technologies for discovering compounds that reduce the fat content of human fat cells from J&J's compound collection.

In addition, AdipoGenix has been characterizing the mechanisms of action and identifying molecular targets for the highest priority of the active compounds that were discovered.

The milestone was for the identification of the molecular target for one of J&J's active compounds that was discovered earlier in the collaboration.

"This is the third milestone that we have achieved in our alliance with J&J, and this achievement provides further validation for our capability to discover compounds that have a beneficial effect on fat cells, and to define mechanisms and molecular targets for active compounds," said Ed Cannon, Ph.D., CEO of AdipoGenix.

Monique Berwaer, Principal Scientist and Metabolic Diseases Team Leader, Johnson & Johnson Pharmaceutical Research and Development commented, "AdipoGenix's human fat cell-based discovery technology is unique and we believe that treating obesity by targeting human fat with pharmaceuticals that reduce fat content is distinctive and an important new approach for combating the growing obesity epidemic."

Advertisement